Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423980 · ClinicalTrials.gov registry record · Phase 2
G-Pen™ for Hypoglycemia Rescue in T1D Patients
A Phase 2 study of Hypoglycemia, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02423980: Completed Phase 2 study of Hypoglycemia, sponsored by Xeris Pharmaceuticals.
NCT02423980 is a Phase 2 study of Hypoglycemia that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 7 participants, below the 507-participant average among 40 other Hypoglycemia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02423980, a Phase 2 study of Hypoglycemia, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart. Subjects will receive a single injection of G-Pen™ (glucagon injection) at each visit.
Primary Outcome
For 90 minutes following treatment, plasma glucose was measured every 5 minutes, with an increase in plasma glucose to \>70 mg/dL within 30 minutes of treatment being considered a positive response.
Conditions Studied
Interventions
- DRUG Glucagon
Study Locations (1)
California
- Diablo Clinical Research, Inc. - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT02423980 record still lists
NCT02423980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 507-participant average among 40 other Hypoglycemia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Glucagon is the first listed.
NCT02423980 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02423980 about?
NCT02423980 is a clinical study titled "G-Pen™ for Hypoglycemia Rescue in T1D Patients". This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart. Subjects will receive a single injection of G-Pen™ (glucagon injection) at each visit.
What is the current status of trial NCT02423980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-04. Estimated completion is 2015-06.
What conditions does trial NCT02423980 study?
This clinical trial studies the following conditions: Hypoglycemia.
What interventions are being tested in trial NCT02423980?
The interventions under investigation include: Glucagon (DRUG).
Who is sponsoring clinical trial NCT02423980?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02423980 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02423980's enrollment target sits among peer trials
7 38th of 40 higher than 3 of 40 other Hypoglycemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoglycemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
COMPLETED · Phase 2
-
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
COMPLETED · Phase 2
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia